Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Revvity Inc. (RVTY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: RVTY (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $124.18
1 Year Target Price $124.18
| 10 | Strong Buy |
| 2 | Buy |
| 7 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -28.98% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 11.53B USD | Price to earnings Ratio 40.42 | 1Y Target Price 124.18 |
Price to earnings Ratio 40.42 | 1Y Target Price 124.18 | ||
Volume (30-day avg) 19 | Beta 0.97 | 52 Weeks Range 87.70 - 129.33 | Updated Date 06/30/2025 |
52 Weeks Range 87.70 - 129.33 | Updated Date 06/30/2025 | ||
Dividends yield (FY) 0.29% | Basic EPS (TTM) 2.42 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 10.35% | Operating Margin (TTM) 12.21% |
Management Effectiveness
Return on Assets (TTM) 2.03% | Return on Equity (TTM) 3.82% |
Valuation
Trailing PE 40.42 | Forward PE 19.88 | Enterprise Value 13717755141 | Price to Sales(TTM) 4.16 |
Enterprise Value 13717755141 | Price to Sales(TTM) 4.16 | ||
Enterprise Value to Revenue 4.95 | Enterprise Value to EBITDA 16.21 | Shares Outstanding 117870000 | Shares Floating 117227270 |
Shares Outstanding 117870000 | Shares Floating 117227270 | ||
Percent Insiders 0.35 | Percent Institutions 99.37 |
Analyst Ratings
Rating 4 | Target Price 124.18 | Buy 2 | Strong Buy 10 |
Buy 2 | Strong Buy 10 | ||
Hold 7 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Revvity Inc.
Company Overview
History and Background
Revvity Inc., formerly PerkinElmer, was founded in 1931. Originally known for analytical instruments, it evolved through strategic acquisitions and divestitures to focus on life sciences and diagnostics. In 2023, it rebranded to Revvity to reflect its focus on health science solutions.
Core Business Areas
- Life Sciences: Provides reagents, assays, instruments, and software for drug discovery, research, and applied markets. This segment focuses on improving understanding of disease mechanisms and developing new therapies.
- Diagnostics: Offers newborn screening, reproductive health, and infectious disease testing solutions. The segment's products enable earlier detection and improved patient outcomes.
Leadership and Structure
Prahlad Singh is the CEO. The company is structured with functional departments such as R&D, Sales, Marketing, and Operations, alongside the Life Sciences and Diagnostics business units.
Top Products and Market Share
Key Offerings
- Newborn Screening: Revvity is a leading provider of newborn screening solutions, helping detect metabolic disorders early. Market share is significant in this area, estimated at 30-40% globally. Competitors include Agilent and Waters Corporation.
- Immunoassays: Offers a broad portfolio of immunoassay kits and platforms for research and clinical diagnostics. Market share is estimated between 10-15%. Competitors include Roche and Abbott.
- Cell Analysis Instruments: Includes flow cytometers, plate readers, and other instruments used in cell biology research and drug discovery. Market share estimated at 5-10%. Competitors include Thermo Fisher Scientific and BD Biosciences
Market Dynamics
Industry Overview
The life sciences and diagnostics industries are experiencing growth due to increasing healthcare spending, aging populations, and advancements in technology. Personalized medicine and drug discovery are key drivers.
Positioning
Revvity is positioned as a leading provider of innovative solutions for life sciences research and diagnostics, focusing on high-growth segments like genomics, proteomics, and cell biology. Its competitive advantages include a broad product portfolio and a strong global presence.
Total Addressable Market (TAM)
The total addressable market for life sciences and diagnostics is estimated to be several hundred billion dollars. Revvity is positioned to capture a significant share of this market through strategic acquisitions and organic growth initiatives.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Broad product portfolio
- Global presence
- Focus on innovation
- Expertise in both life sciences and diagnostics
Weaknesses
- Integration challenges from acquisitions
- Dependence on specific markets (e.g., newborn screening)
- Price competition
- Customer concentration
Opportunities
- Expanding into emerging markets
- Developing new diagnostic tests
- Leveraging data analytics
- Partnerships with pharmaceutical companies
- Growth of personalized medicine
Threats
- Regulatory changes
- Technological obsolescence
- Economic downturns
- Increased competition
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- TMO
- DHR
- ABT
- ROCHE.SW
Competitive Landscape
Revvity faces strong competition from larger players. Its strengths lie in its specialized product portfolio and focus on specific market niches. A weakness is it's smaller size versus the competitors.
Major Acquisitions
BioLegend
- Year: 2021
- Acquisition Price (USD millions): 5250
- Strategic Rationale: Expanded Revvity's offering in cell biology and immunology, enhancing its position in biopharmaceutical research.
Nexcelom Bioscience
- Year: 2021
- Acquisition Price (USD millions): 260
- Strategic Rationale: Strengthened Revvity's cell counting and analysis capabilities.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by acquisitions and organic revenue increases.
Future Projections: Future growth projections depend on market conditions and company performance.
Recent Initiatives: Recent initiatives include rebranding, strategic acquisitions, and investments in R&D.
Summary
Revvity is a life sciences and diagnostics company with a diversified product portfolio and a global presence. The company benefits from its focus on innovation and strategic acquisitions. However, it faces competition from larger players and needs to manage integration risks effectively. Overall Revvity is well positioned for long term growth in the market it has a competitive edge in and should continue on it's current trajectory.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Analyst Reports
- Industry Publications
- SEC Filings
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance may change over time.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Revvity Inc.
Exchange NYSE | Headquaters Waltham, MA, United States | ||
IPO Launch date 1983-04-06 | CEO, President & Director Dr. Prahlad R. Singh Ph.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 11000 | Website https://www.revvity.com |
Full time employees 11000 | Website https://www.revvity.com | ||
Revvity, Inc. provides health sciences solutions, technologies, and services worldwide. The company's Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services. Its Diagnostics segment offers instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. It also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for use in oncology, screening newborns for rare genetic conditions, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific, BioQule, BoBs, chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPatternTM, Evolution Evoya, explorer, Fontus, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Omni Bead Ruptor, Omni Bead Ruptor Elite, Omni Tip, Pannoramic, Panthera Puncher, PG-Seq, PG-Find, PreNAT II, Prime, Protein Clear, ProteinEXact, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord, VICTOR2D, and Zephyr brands. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Mass
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.